Clinical Trial Update: CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of EGFRvIII-targeted CAR T cell therapy for malignant gliomas expressing EGFRvIII has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Glioma

Drugs mentioned

• CAR T Cell Receptor Immunotherapy Targeting EGFRvIII (EGFRvIII-targeted CAR T cells)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Malignant Glioma, Glioblastoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-08-21